Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2018 June;59(3) > The Journal of Cardiovascular Surgery 2018 June;59(3):373-80

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

 

REVIEW  CURRENT STATUS OF TRANSCATHETER AORTIC VALVE IMPLANTATION 

The Journal of Cardiovascular Surgery 2018 June;59(3):373-80

DOI: 10.23736/S0021-9509.18.10489-7

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

What are the remaining limitations of TAVI?

Chiara DE BIASE 1, 2, Antonios MASTROKOSTOPOULOS 1, Raphael PHILIPPART 1, Laurent BONFILS 1, Pierre BERTHOUMIEU 1, Nicolas DUMONTEIL 1

1 Groupe Cardio-Vasculaire Interventionel (GCVI), Clinique Pasteur, Toulouse, France; 2 Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy


PDF


Transcatheter aortic valve implantation (TAVI) is a recognized therapy for patients with symptomatic severe aortic stenosis (AS). TAVI is superior compared to medical therapy as for mortality in extreme-risk patients, is non-inferior or superior to surgery in high-risk patients and non-inferior to surgery in intermediate-risk patients. However, several limitations affect outcomes after TAVI. Adverse events related to this procedure, like vascular complications, need for pacemaker implantation, paravalvular regurgitation, can be factors limiting TAVI treatment in younger patients at lower risk, as well as uncertainties regarding valve durability. This review tries to figure out some of the main complications still unsolved after TAVI.


KEY WORDS: Heart valve diseases - Transcatheter aortic valve implantation - Aortic valve stenosis

inizio pagina